However, the exploitation of peroxisome proliferator-activated receptor-γ (PPARγ) signaling in a therapeutic setting of NAFLD has been hampered by the limited understanding of its regulatory mechanisms and the lack of its precise function in liver-adipose tissue crosstalk. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.